Chlorendic acid, also known as 2,3,4,5,6-pentachloro-1-hydroxycyclohex-2-ene-1-carboxylic acid, is a chlorinated cyclic carboxylic acid. It is synthesized through a multi-step process involving the chlorination of cyclopentadiene followed by oxidation. Chlorendic acid has been used in various applications, including the production of flame retardants, plasticizers, and epoxy resins. Its effectiveness as a flame retardant is attributed to its high chlorine content, which acts as a halogenated fire suppressant. Studies on chlorendic acid have focused on its environmental impact, particularly its potential to contaminate water sources and bioaccumulate in organisms. Research has also investigated its toxicity and carcinogenic potential. The importance of studying chlorendic acid stems from its widespread use in industrial applications and the potential risks associated with its release into the environment. These studies aim to assess the environmental fate and potential health risks associated with chlorendic acid.'
chlorendic acid: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
chlorendic acid : A bridged organochlorine compound resulting from the Diels-Alder reaction of hexachlorocyclopentadiene with maleic anhydride followed by hydrolysis of the resulting anhydride. A chemical intermediate used in the preparation of fire-retardant polyester resins and plasticisers. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 8266 |
| CHEMBL ID | 462314 |
| CHEBI ID | 76603 |
| SCHEMBL ID | 159505 |
| MeSH ID | M0108455 |
| Synonym |
|---|
| smr001224506 |
| MLS002152895 , |
| nsc-41876 |
| nsc41876 |
| nci-c55072 |
| kyselina het |
| nsc-22231 |
| 115-28-6 |
| kyselina 3,4,5,6,7,7-hexachlor-.delta.(sup 4)-tetrahyroftalova |
| nsc22231 |
| het acid |
| hexachloroendomethylenetetrahydrophthalic acid |
| wln: l55 a cutj ag ag bg cg dg eg fvq gvq |
| chlorendic acid |
| NCI60_001839 |
| hsdb 2915 |
| ccris 896 |
| chlorendic acid (van) |
| 1,4,5,6,7,7-hexachloro-8,9,10-trinorborn-5-ene-2,3-dicarboxylic acid |
| nsc 22231 |
| kyselina 3,6-endomethylen-3,4,5,6,7,7-hexachlor-delta(sup 4)-tetrahydroftalova [czech] |
| bicyclo(2.2.1)hept-5-ene-2,3-dicarboxylic acid, 1,4,5,6,7,7-hexachloro- |
| kyselina 3,6-endomethylen-3,4,5,6,7,7-hexachlor-delta(sup 4)-tetrahyroftalova [czech] |
| einecs 204-078-9 |
| 1,4,5,6,7,7-hexachlorobicyclo(2.2.1)-5-heptene-2,3-dicarboxylic acid |
| kyselina het [czech] |
| 1,4,5,6,7,7-hexachloro-5-norbornene-2,3-dicarboxylic acid |
| kyselina 1,2,3,4,7,7-hexachlorbicyklo(2,2,1)hept-2-en-5,6-dikarboxylova [czech] |
| hexachloro-endo-methylenetetrahydrophthalic acid |
| nsc-22225 |
| 1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid |
| 5-norbornene-2,3-dicarboxylic acid, 1,4,5,6,7,7-hexachloro- |
| bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid, 1,4,5,6,7,7-hexachloro- |
| NCGC00091276-01 |
| inchi=1/c9h4cl6o4/c10-3-4(11)8(13)2(6(18)19)1(5(16)17)7(3,12)9(8,14)15/h1-2h,(h,16,17)(h,18,19 |
| nsc519 |
| mls002637518 , |
| nsc-519 |
| 1,5,6,7,7-hexachloro-5-norbornene-2,3-dicarboxylic acid |
| STK266636 |
| 1,2,3,4,7,7-hexachlorobicyclo[2.2.1]hept-2-ene-5,6-dicarboxylic acid |
| AKOS003363272 |
| 7374-78-9 |
| H0054 |
| chebi:76603 , |
| CHEMBL462314 |
| NCGC00091276-03 |
| C19204 |
| HMS3039F04 |
| cas-115-28-6 |
| tox21_202339 |
| dtxsid2020268 , |
| NCGC00259888-01 |
| tox21_300190 |
| dtxcid80268 |
| NCGC00253973-01 |
| kyselina 3,6-endomethylen-3,4,5,6,7,7-hexachlor-delta(sup 4)-tetrahydroftalova |
| kyselina 3,6-endomethylen-3,4,5,6,7,7-hexachlor-delta(sup 4)-tetrahyroftalova |
| kyselina 1,2,3,4,7,7-hexachlorbicyklo(2,2,1)hept-2-en-5,6-dikarboxylova |
| nsc 41876 |
| FT-0626941 |
| bdbm94954 |
| cid_8266 |
| 1,2,3,4,7,7-hexakis(chloranyl)bicyclo[2.2.1]hept-2-ene-5,6-dicarboxylic acid |
| SCHEMBL159505 |
| AKOS016843860 |
| bicyclo[2.2.1]-5-heptene-2,3-dicarboxylic acid, 1,4,5,6,7,7-hexachloro- |
| 1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid # |
| kyselina 3,6-endomethylen-3,4,5,6,7,7-hexachlor-.delta.(4)-tetrahyroftalova |
| kyselina 3,6-endomethylen-3,4,5,6,7,7-hexachlor-.delta.(4)-tetrahydroftalova |
| DJKGDNKYTKCJKD-UHFFFAOYSA-N |
| AS-72784 |
| EN300-24974 |
| 1,4,5,6,7,7-hexachlorobicyclo-(2,2,1)-hept-5-ene-2,3-dicarboxylic acid |
| Q1854296 |
| D90788 |
| 1,4,5,6,7,7-hexachlorobicyclo[2.2.1]-hept-5-ene-2,3-dicarboxylic acid |
| 1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dosing was for 7 days at the dose and route employed previously in the NTP cancer bioassays." | ( Hepatic ploidy, nuclearity, and distribution of DNA synthesis: a comparison of nongenotoxic hepatocarcinogens with noncarcinogenic liver mitogens. Hasmall, SC; Roberts, RA, 1997) | 0.3 |
| Role | Description |
|---|---|
| carcinogenic agent | A role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| organochlorine compound | An organochlorine compound is a compound containing at least one carbon-chlorine bond. |
| dicarboxylic acid | Any carboxylic acid containing two carboxy groups. |
| bridged compound | A polycyclic compound in which two rings have two or more atoms in common. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 0.3162 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 88.7755 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| GLS protein | Homo sapiens (human) | Potency | 17.7828 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| AR protein | Homo sapiens (human) | Potency | 0.1538 | 0.0002 | 21.2231 | 8,912.5098 | AID743063 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 14.1254 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 39.8107 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 17.8426 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 20.4125 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 89.1251 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 86.4900 | 0.0010 | 24.5048 | 61.6448 | AID743212 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 50.1187 | 0.0010 | 19.4141 | 70.9645 | AID588536 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 68.1016 | 0.0007 | 23.0674 | 1,258.9301 | AID743122 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 95.2834 | 0.1000 | 28.9256 | 213.3130 | AID720502 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 44.6684 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 0.8199 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| low molecular weight phosphotyrosine protein phosphatase isoform c | Homo sapiens (human) | IC50 (µMol) | 80.0000 | 4.9700 | 11.2567 | 19.6000 | AID652005 |
| Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) | IC50 (µMol) | 80.0000 | 2.8600 | 9.6336 | 17.2000 | AID651700 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| acid phosphatase activity | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| protein tyrosine phosphatase activity | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| non-membrane spanning protein tyrosine phosphatase activity | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| protein binding | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytoplasm | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| cytosol | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| cytoplasmic side of plasma membrane | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| sarcolemma | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| extracellular exosome | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID393936 | Antibacterial activity against Escherichia coli 1411 after 18 hrs by broth microdilution method | 2009 | Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5 | Discovery of new inhibitors of the bacterial peptidoglycan biosynthesis enzymes MurD and MurF by structure-based virtual screening. |
| AID393938 | Antibacterial activity against Staphylococcus aureus 8325-4 after 18 hrs by broth microdilution method | 2009 | Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5 | Discovery of new inhibitors of the bacterial peptidoglycan biosynthesis enzymes MurD and MurF by structure-based virtual screening. |
| AID393937 | Antibacterial activity against AcrAB deficient Escherichia coli SM1411 after 18 hrs by broth microdilution method | 2009 | Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5 | Discovery of new inhibitors of the bacterial peptidoglycan biosynthesis enzymes MurD and MurF by structure-based virtual screening. |
| AID393764 | Inhibition of Escherichia coli MurD assessed as residual activity at 250 uM by malachite green assay | 2009 | Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5 | Discovery of new inhibitors of the bacterial peptidoglycan biosynthesis enzymes MurD and MurF by structure-based virtual screening. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.91) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (6.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (93.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||